Compare AbbVie Inc (ABBV) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Zoom Video Communications, Inc. — how do they compare? AbbVie Inc trades at $248.8 (market cap $441.94B), while Zoom Video Communications, Inc. trades at $104.49 (market cap $31.10B). The key difference: AbbVie Inc is far larger — about 14.2× Zoom Video Communications, Inc.'s market cap, and AbbVie Inc pays a 2.77% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | ZM | |
|---|---|---|
Market Cap | $441.94B | $31.10B |
Sector | Health | Technology |
52-Week High | $263.58 | $111.88 |
52-Week Low | $197.38 | $69.96 |
Enterprise Value | $506.19B | $23.44B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Zoom Communications (ZM) trades at $107.20, up 2.58% today, with a bullish technical signal from moving averages and a consensus analyst price target of $118.79. The stock shows strong profitability with a net income margin of 41.99% and ROE of 21.95%, supported by recent earnings beats. However, insider selling and mixed oscillators suggest caution amid overbought conditions.
Outlook: ZM offers growth potential with solid fundamentals and AI-driven product expansions, but risks include competitive pressures and volatile cash flows. Investors should weigh the high valuation (P/E 15.62) against earnings consistency and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
